A review of an unfavorable subset of breast cancer: Estrogen receptor positive progesterone receptor negative

Oncologist

Volumn 16, Issue 3, 2011, Pages 276-285

  Thakkar, Jigisha P ^a   Mehta, Divyesh G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Estrogen receptor; Gefitinib; Growth factors; Progesterone receptor

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; GEFITINIB; GROWTH FACTOR; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; DISEASE ACTIVITY; DRUG MECHANISM; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ESTROGEN BLOOD LEVEL; GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENOMIC INSTABILITY; GROWTH RATE; HETEROZYGOSITY LOSS; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROGESTERONE RECEPTOR GENE; PROGNOSIS; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 79952996052     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0302     Document Type: Review

References (34)

1. Nakamura Y, Oka M, Soda H et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65:1541-1546.
2. Daniel AR, Qiu M, Faivre EJ et al. Linkage of progestin and epidermal growth factor signaling: Phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 2007;72:188-201.
3. Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-870s.
4. Cui X, Schiff R, Arpino G et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23:7721-7735.
5. Dunbier AK, Anderson H, Folkerd EJ et al. Expression of estrogen responsive genes in breast cancers correlates with plasma estradiol levels in postmenopausal women. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 13, 2008.
6. Zhang Y, Su H, Rahimi M et al. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer 2009;125: 2021-2028.
7. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-1261.
8. Neven P, Pochet N, Drijkoningen M et al. Progesterone receptor in estrogen receptor-positive breast cancer: The association between HER-2 and lymph node involvement is age related. J Clin Oncol 2006;24:2595; author reply 2595-2597.
9. Viale G, Regan MM, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25: 3846-3852.
10. Creighton CJ, Kent Osborne C, van de Vijver MJ et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009;114:287-299.
11. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
12. Chin K, DeVries S, Fridlyand J et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541.
13. Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246.
14. Yu KD, Liu GY, Di GH et al. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast 2007;16:307-315.
15. Suzuki R, Orsini N, Saji S et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009;124:698-712.
16. Larsson SC, Bergkvist L, and Wolk A. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. Int J Cancer 2009;125:153-157.
17. Rose-Hellekant TA, Skildum AJ, Zhdankin O et al. Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor- positive/progesterone receptor-negative mammary tumors. Cancer Prev Res (Phila) 2009;2:496-502.
18. Dowsett M, On behalf of the ATAC trialists group. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(suppl 1):S7.
19. Cristofanilli M, Valero V, Mangalik A et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16:1904-1914.
20. Johnston SRD. Endocrine therapy combined with signal transduction inhibitors a means to overcome resistance. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11, 2008.
21. Osborne K, Neven P et al. Randomised phase II study of gefitinib or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Abstract presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
22. Polychronis A, Sinnett HD, Hadjiminas D et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogenreceptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6:383-391.
23. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-2637.
24. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
25. Pierce JP, Stefanick ML, Flatt SW et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007;25:2345-2351.
26. - breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically assigned PR status. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14, 2007.
27. Elledge R. Hormone receptors in breast cancer: Measurement and clinical implications. Available at http://www.uptodate.com/contents/hormonereceptors-in-breast-cancer-measurement-and-clinical-implications?source=search_result&selectedTitle=1%7E150, accessed February 3, 2011.
28. Osborne CK, Schiff R, Arpino G et al. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005;14:458-465.
29. Elledge RM, Green S, Pugh R et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer 2000;89:111-117.
30. Rakha EA, El-Sayed ME, Green AR et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-4778.
31. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979.
32. Cui X, Zhang P, Deng W et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-588.
33. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423.
34. Hoadley K, Weigman V, Fan C et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258.